246 filings
8-K
LUMO
Lumos Pharma Inc
18 Apr 24
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
4:53pm
8-K
LUMO
Lumos Pharma Inc
20 Mar 24
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
4:27pm
8-K
LUMO
Lumos Pharma Inc
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
8-K
LUMO
Lumos Pharma Inc
4 Jan 24
Regulation FD Disclosure
4:34pm
8-K
LUMO
Lumos Pharma Inc
15 Nov 23
Other Events
4:38pm
8-K
pgu5xg rj
7 Nov 23
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
4:42pm
8-K
84nmszu3ojf wnbc50
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
8-K
gh2o198de
26 Sep 23
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
4:34pm
8-K
1xpbw8st78fwrbyi
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm
8-K
2eikql4c
28 Jun 23
Lumos Pharma Announces Departure of Chief Medical Officer
4:26pm
8-K
2pbz09rbddkcgp
21 Jun 23
Lumos to Highlight New LUM-201 Data and Analysis Presented
5:10pm
8-K
pst33bb 6tywzl
15 May 23
Submission of Matters to a Vote of Security Holders
4:26pm
8-K
vx6x x8za
8 May 23
Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at
4:01pm
8-K
fmef04aouhps5f8m43a
3 May 23
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
4:49pm
8-K
7b7izlu
7 Mar 23
Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology
6:02am
8-K
d1bwdwgp j6
1 Mar 23
Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates
4:51pm
8-K
i7revv3 pnqnga9pt
28 Feb 23
Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD
12:00am
8-K
xv4ls6 nf
12 Dec 22
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
5:20pm
8-K
h5b05 lo4xfmjyxr
30 Nov 22
Other Events
6:27pm
8-K
70mk513
14 Nov 22
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
7:29am